Clinical Trials, Phase IV as Topic
"Clinical Trials, Phase IV as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
Descriptor ID |
D017327
|
MeSH Number(s) |
E05.318.760.250.500.230 E05.337.800.200 N05.715.360.775.088.500.230 N06.850.520.450.250.250.230
|
Concept/Terms |
Drug Evaluation, FDA Phase IV as Topic- Drug Evaluation, FDA Phase IV as Topic
- Evaluation Studies, FDA Phase 4 as Topic
- Drug Evaluation, FDA Phase 4 as Topic
- Evaluation Studies, FDA Phase IV as Topic
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase IV as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase IV as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase IV as Topic" by people in this website by year, and whether "Clinical Trials, Phase IV as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase IV as Topic" by people in Profiles.
-
National Liver Cancer Screening Trial (TRACER) study protocol. Hepatol Commun. 2024 Nov 01; 8(11).
-
Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study. BMJ Open. 2023 06 12; 13(6):e071311.
-
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor a. Clin Cancer Res. 2020 06 15; 26(12):2986-2996.
-
Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013 Mar; 60(3):371-6.